whitepaper
ebook: Maximizing preclinical confidence in target efficacy and safety
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
List view / Grid view
Artificial Intelligence
article
How the AI revolution can accelerate early drug discovery
Rob Scoffin and Matthew Habgood from solutions provider Cresset look to the future of drug discovery and the roles that artificial intelligence and machine learning could play.
news
Artificial intelligence cell analysis for swift blood disease diagnosis
Researchers from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an artificial intelligence (AI) system capable of identifying and characterising white and red blood cells within microscopic images of blood samples. This AI algorithm holds the potential to aid medical professionals in diagnosing blood…
article
SERS-artificial intelligence method for early detection of cancer
Scientists have developed a promising new method to detect cancer at very early stages during routine health screens, paving way for improved treatment and recovery.
podcasts
Episode 20- Regulations on artificial intelligence- impact on drug discovery
Tune in to this episode to hear experts discussing the hot topic that is AI and how AI technology is used in drug discovery, looking specifically at how Biotechs & Pharma are trying to keep up with emerging technology.
article
Navigating the challenges and opportunities of AI in drug development and personalised medicine
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
article
Biochemical assays and deep cyclic inhibition in cancer treatment
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.
article
Unleashing the power of AI in target discovery and resilience against disease
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…
news
US grant supports merging of maths and AI to push frontiers of science
Cornell University launches $11.3 Million Scientific Artificial Intelligence Centre to unlock the potential of human-AI collaboration in scientific discoveries.
article
The power of single-cell technologies
Drug Target Review’s Taylor Mixides interviews Cellarity's CEO Fabrice Chouraqui about applying Artificial Intelligence (AI) and Machine Learning (ML) to evolving single-cell technologies.
article
Drug Target Review Screening eBook 2023
27 June 2023 | By
In this eBook, uncover the transformative potential of AI/ML in single-cell technologies and gain insights into disease progression.
news
AI-based technology offers accurate analysis of cardiac disease
A study out of South Korea outlines the potential of an AI-based imaging tool for diagnosing and analysing cardiac disease.
article
Game-changing pan-TEAD inhibitor for solid tumours
Insilico Medicine has announced the nomination of ISM6331 as a potential best-in-class pan-TEAD inhibitor for the treatment of advanced solid tumours.
article
Challenges and promises of personalised precision medicine
Drug Target Review’s Taylor Mixides exclusively interviews Neil Thomas, Partner and Head of Healthcare and Life Sciences for EMEA at Infosys Consulting, on personalised precision medicine, its advances, challenges and the future.
article
2023 drug discovery forecast: emerging trends and disruptors revolutionising the industry
With advancements in artificial intelligence, precision medicine and gene editing, the field of drug discovery is undergoing a rapid transformation. In this article, Drug Target Review’s Izzy Wood gets the insider knowledge from industry leaders at SLAS 2023, who are experiencing these changes first hand.